Payment overview · 2025
General Payments
$1,113.76
44 reported records · 10 companies
Healthcare provider profile · identity verified
Peter James Bessas, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · VANCOUVER, WA · NPI 1992756498
Verified facts
What the public records show
CMS Open Payments records show Peter James Bessas, M.D. received $1,113.76 in general payments during 2025 across 44 reported records.
AstraZeneca Pharmaceuticals LP accounted for 28.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $319.69 | 28.7% | 13 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $228.39 | 20.5% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $182.44 | 16.4% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $139.16 | 12.5% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $56.57 | 5.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $52.81 | 4.7% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $37.68 | 3.4% | 2 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $37.25 | 3.3% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.77 | 2.8% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $29.00 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,113.76 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $301.63 | 12 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $182.44 | 8 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $182.44 | 8 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $150.14 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $81.46 | 3 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $78.25 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $57.70 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $56.57 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $56.57 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $52.81 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $37.68 | 2 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $37.25 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $30.77 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone Hcl | Oxycodone Hcl | 206 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 132 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 128 | 17 |
| Levothyroxine Sodium | Levothyroxine Sodium | 109 | 26 |
| Alprazolam | Alprazolam | 93 | 15 |
| Losartan Potassium | Losartan Potassium | 86 | 24 |
| Gabapentin | Gabapentin | 81 | 21 |
| Trazodone Hcl | Trazodone Hcl | 71 | 15 |
| Atorvastatin Calcium | Atorvastatin Calcium | 68 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 68 | 18 |
| Metoprolol Succinate | Metoprolol Succinate | 67 | 16 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 64 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 63 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 54 | 23 |
| Clonazepam | Clonazepam | 54 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 49 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 48 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 46 | suppressed |
| Prednisone | Prednisone | 46 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 46 | 14 |
| Lisinopril | Lisinopril | 44 | 12 |
| Tramadol Hcl | Tramadol Hcl | 44 | suppressed |
| Diazepam | Diazepam | 38 | suppressed |
| Meloxicam | Meloxicam | 36 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | suppressed |
| Methylprednisolone | Methylprednisolone | 35 | 22 |
| Sertraline Hcl | Sertraline Hcl | 35 | suppressed |
| Metformin Hcl | Metformin Hcl | 32 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 32 | suppressed |
| Omeprazole | Omeprazole | 31 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 30 | suppressed |
| Fluconazole | Fluconazole | 29 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 27 | suppressed |
| Jardiance | Empagliflozin | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 25 | suppressed |
| Lorazepam | Lorazepam | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 15 |
| Clonidine Hcl | Clonidine Hcl | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | 13 |
| Pregabalin | Pregabalin | 24 | suppressed |
| Azithromycin | Azithromycin | 23 | 19 |
| Potassium Chloride | Potassium Chloride | 23 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 22 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 22 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Simvastatin | Simvastatin | 21 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 20 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 20 | suppressed |
| Ozempic | Semaglutide | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Allopurinol | Allopurinol | 19 | suppressed |
| Carisoprodol | Carisoprodol | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Buprenorphine | Buprenorphine | 18 | suppressed |
| Eliquis | Apixaban | 18 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 18 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Xyosted | Testosterone Enanthate | 13 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Famotidine | Famotidine | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Carvedilol | Carvedilol | 11 | suppressed |
| Eplerenone | Eplerenone | 11 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,113.76 · 44 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Auvelity, CAPLYTA, Cologuard Collection Kit, NURTEC ODT, OTEZLA, Ozempic, REPATHA, REZDIFFRA, Sunosi, Wegovy, ZAVZPRET, ZEPBOUND | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error